

Thalidomide-O-C7-acid Biochemical

Thalidomide-O-C7-acid

CATALOG #
AAA228184


PRODUCT SYNONYMS

Thalidomide-O-C7-acid; Thalidomide-O-C7-acid biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	2169266-70-8
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
PROTAC CBP/P300 Degradator-1, CAS 2484739-48-0



Structure
PROTAC CBP/P300 Degradator-1, CAS 2484739-48-0

ADDITIONAL INFORMATION

Related Product Information for Thalidomide-O-C7-acid biochemical	Thalidomide-O-C7-acid is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.
References	1. Jing Liu, et al. Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use. WO2020173440A1.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.